<DOC>
	<DOCNO>NCT01029743</DOCNO>
	<brief_summary>This study identify follow problem question respect safety effectiveness Xarelto comparison pharmacologic agent prophylaxis venous thromboembolism ( VTE ) large sample patient undergo elective total hip replacement ( THR ) total knee replacement ( TKR ) real-life condition register indication ( ) require Korean Food Drug Administration ( KFDA ) . 1 . Known unknown adverse reaction , especially serious adverse reaction 2 . Incidence adverse reaction routine drug use 3 . Factors may affect safety drug 4 . Factors may affect effectiveness drug 5 . Other safety information relate overuse , drug interaction laboratory abnormality 6 . Other adverse reaction</brief_summary>
	<brief_title>Xarelto Regulatory Post-Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Female male patient &gt; /= 18 year age undergo elective total hip replacement total knee replacement receive Xarelto pharmacologic standard care Venous Thromboembolism ( VTE ) prophylaxis , consent participate study Patients hypersensitivity pharmacologic VTE prophylaxis treatment Patients clinically significant active bleeding ( e.g. , intracranial bleeding , gastrointestinal bleeding ) Patients significant hepatic disease associate coagulopathy lead clinically relevant bleed risk Pregnant lactate woman Patients hereditary problem lactose galactose intolerance ( e.g. , Lapp lactase deficiency glucosegalactose malabsorption )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TKR ( Total Knee Replacement )</keyword>
	<keyword>THR ( Total Hip Replacement )</keyword>
	<keyword>VTE ( Venous Thromboembolism )</keyword>
	<keyword>LMWH ( Low Molecular Weight Heparin )</keyword>
	<keyword>VKA ( Vitamin K antagonist )</keyword>
</DOC>